Protective Immunity to Chlamydia trachomatis Genital Infection: Evidence from Human Studies
Open accessThe DOI matches its Crossref record.
Abstract
Background. Some screening and treatment programs implemented to control Chlamydia trachomatis genital infections and their complications have shown initial reductions in infection prevalence, followed by increases to preprogram levels or higher. One hypothesis is that treatment shortens duration of infection, attenuates development of protective immunity, and thereby, increases risk of reinfection. Methods. A literature review was undertaken to assess evidence supporting the concept of protective immunity,its characteristics, and its laboratory correlates in human chlamydial infection. The discussion is organized around key questions formulated in preparation for the Chlamydia Immunology and Control Expert Advisory Meeting held by the Centers for Disease Control and Prevention in April 2008. Results. Definitive human studies are not available, but cross-sectional studies show that chlamydia prevalence,organism load, and concordance rates in couples decrease with age, and organism load is lower in those with repeat infections, supporting the concept of protective immunity. The protection appears partial and can be overcome after reexposure, similar to what has been found in rodent models of genital infection. No data are available to define the duration of infection required to confer a degree of immunity or the time course of immunity after resolution of untreated infection. In longitudinal studies involving African sex workers, a group presumed to have frequent and ongoing exposure to chlamydial infection, interferon-g production by peripheral blood mononuclear cells in response to chlamydial heat-shock protein 60 was associated with low risk of incident infection.In cross-sectional studies, relevant T helper 1-type responses were found in infected persons, paralleling the studies in animal models. Conclusions. The data support the concept that some degree of protective immunity against reinfection develops after human genital infection, although it appears, at best, to be partial. It is likely that factors besides population levels of immunity contribute to trends in prevalence observed in screening and treatment programs.Future studies of protective immunity in humans will require longitudinal follow-up of individuals and populations,frequent biological and behavioral sampling, and special cohorts to help control for exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Price, M. J., Ades, A., Soldan, K., Welton, N. J., Macleod, J., Simms, I., DeAngelis, D., Turner, K. M., & Horner, P. J. (2016) · Health Technology Assessment · doi:10.3310/hta20220 · Cited by 494
A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells
Stary, G., Olive, A., Radovic-Moreno, A. F., Gondek, D., Alvarez, D., Basto, P. A., Perro, M., Vrbanac, V. D., Tager, A. M., Shi, J., et al. (2015) · Science · doi:10.1126/science.aaa8205 · Cited by 379
“Recent clinical evidence suggests that humans develop at least partially protective immunity upon clearance of genital Ct infection, whereby interferon (IFN)-γ production, presumably by T-helper 1 (TH1) cells, was inversely correlated with the risk for reinfection (34-36).”
BackgroundToward global prevention of sexually transmitted infections (STIs): The need for STI vaccines
Gottlieb, S. L., Low, N., Newman, L. M., Bolan, G., Kamb, M., & Broutet, N. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.07.087 · Cited by 162
Althaus, C. L., Turner, K. M., Mercer, C. H., Auguste, P., Roberts, T. E., Bell, G., Herzog, S. A., Cassell, J. A., Edmunds, W. J., White, P. J., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18020 · Cited by 101
“Whether or not spontaneous resolution of chlamydia infection is followed by a period of immunity is a matter of debate.(96,110) Assuming no development of immunity resulted in unrealistically high chlamydia prevalence rates in individuals with high sexual activity.”
BackgroundLarena, M., Regner, M., & Lobigs, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044834 · Cited by 38
Metadata
- Authors
- Batteiger, B. E., Xu, F., Johnson, R. E., & Rekart, M. L.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-15
- Volume
- 201
- Issue
- S2
- Pages
- 178-189
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2096696889
- Cited by
- 141
- References
- 0
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective Immunity to Chlamydia trachomatis Genital Infection: Evidence from Human Studies. https://app.cochat.ai/papers/10.1086/652400
- The paper
- Batteiger, B. E., Xu, F., Johnson, R. E., & Rekart, M. L. (2010). Protective Immunity to Chlamydia trachomatis Genital Infection: Evidence from Human Studies. The Journal of Infectious Diseases. https://doi.org/10.1086/652400
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.